درباره این اپیزود
On this episode, I speak with Tim Guilliams and David Brown of Healx. Healx uses AI to repurpose existing drugs for rare diseases. They claim their approach can bring new treatments to patients 80% faster and 90% cheaper. On this episode, you’ll learn how rare diseases are surprisingly common, why drug repurposing holds promise to treat them, and how Healx uses AI to do it. And you will, I hope, be inspired by a powerful example of AI's potential in healthcare.
This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 15 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .
This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the time, uncertainty, and cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 15 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .
انگلیسی
ایالات متحده آمریکا
رونوشت 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
جستجوی اپیزودهای گذشته
اپیزودهای قبلی Artificial Intelligence in Drug Discovery را جستجو کن.
قسمت های دیگر در این پادکست
On this episode, I speak with Leila Pirhaji, founder and CEO of ReviveMed ( www.revive-med.com ). ReviveMed uses artificial intelligence to unlock the therapeutic potential of metabolomics. Before learning about ReviveMed, I knew little about metabolomics. Leila is an articulate and enthusiastic te…
On this episode, I speak with Mostapha Benhenda of Startcrowd ( http://www.startcrowd.club ). In January, Mostapha wrote a controversial article critiquing several research labs ( https://bit.ly/2qINvQ9 ). Some accused him of using the article just to promote his service. Others agreed with his cri…
On this episode, I speak with Shai Shen-Orr, cofounder and chief scientist of CytoReason ( www.cytoreason.com ). CytoReason has created a machine learning model of the immune system. This model can integrate data from multiple sources to support drug discovery, the creation of diagnostic tools, and…
On this episode, I speak with Mauro Cozzi, co-founder of Researchably ( www.researchably.com ). Researchably is a biomedical search engine that uses artificial intelligence to save researchers time—Mauro says up to 90%—searching for scientific papers. I spoke with Mauro about how Researchably got s…
For the inaugural episode of Artificial Intelligence in Drug Discovery, I spoke with Dekel Gelbman, CEO of FDNA ( https://www.fdna.com/ ). FDNA enables precision medicine by using artificial intelligence for next-generation phenotyping. Their technology links genetic traits with phenotypic characte…
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به Simon Smith است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم